Viral load and progression. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714. A fee will apply.

Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Viral load and progression. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714. A fee will apply.

PI Perspect. 1997 Mar;(No 21):6-7. Unique Identifier : AIDSLINE AIDS/97702494

Abstract: Several studies are currently investigating the best ways to use new AIDS drug therapies and handle drug resistance. One study shows that HIV RNA levels in semen strongly correlate with RNA levels in plasma. Other studies report correlations in viral load changes in plasma and lymphoid tissue following combination drug therapy. A study on drug resistance reports that the HIV protease enzyme can develop mutations associated with drug resistance, even prior to administering protease inhibitors. Another study specifically investigating resistance to nelfinavir reveals that people who had multiple mutations were resistant and did not benefit from the drug, while those with only one mutation in the HIV protease enzyme remained sensitive to nelfinavir. Finally, a study reveals that treatment success will be short-lived when therapy fails to fully suppress viral replication, suggesting that waiting for treatment failure (according to the International AIDS Society USE guidelines) to occur is too late.

Keywords: Anti-HIV Agents/ADMINISTRATION & DOSAGE/THERAPEUTIC USE Drug Resistance, Microbial Drug Therapy, Combination Female HIV Infections/DRUG THERAPY/*VIROLOGY HIV Protease Inhibitors/ADMINISTRATION & DOSAGE/THERAPEUTIC USE HIV-1/GENETICS/*ISOLATION & PURIF Human Lymphoid Tissue/*VIROLOGY Mucus/VIROLOGY Mutation RNA, Viral/ANALYSIS/*BLOOD Vagina/SECRETION *Viral Load NEWSLETTER ARTICLE
970830
M9781255

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .